American Century Companies Inc. Lowers Stock Holdings in Health Catalyst, Inc. $HCAT

American Century Companies Inc. trimmed its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 83.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,974 shares of the company’s stock after selling 592,507 shares during the period. American Century Companies Inc.’s holdings in Health Catalyst were worth $534,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in shares of Health Catalyst by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,591,565 shares of the company’s stock valued at $11,252,000 after acquiring an additional 235,686 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Health Catalyst by 8.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company’s stock valued at $442,000 after acquiring an additional 4,798 shares in the last quarter. Northern Trust Corp boosted its holdings in Health Catalyst by 8.5% in the 4th quarter. Northern Trust Corp now owns 526,607 shares of the company’s stock valued at $3,723,000 after purchasing an additional 41,298 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Health Catalyst in the 4th quarter valued at approximately $735,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Health Catalyst in the 4th quarter valued at approximately $92,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on HCAT shares. Evercore ISI lifted their price objective on Health Catalyst from $3.00 to $4.00 and gave the company an “in-line” rating in a report on Thursday, August 28th. BTIG Research restated a “neutral” rating on shares of Health Catalyst in a research report on Friday. Canaccord Genuity Group decreased their price objective on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 29th. Citigroup downgraded shares of Health Catalyst from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $6.50 to $3.50 in a report on Friday, August 8th. Finally, Piper Sandler downgraded shares of Health Catalyst from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $8.00 to $4.00 in a report on Wednesday, August 27th. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $4.73.

Health Catalyst Stock Up 2.4%

Shares of NASDAQ HCAT opened at $3.38 on Friday. Health Catalyst, Inc. has a 12-month low of $2.52 and a 12-month high of $9.24. The company has a market capitalization of $237.85 million, a PE ratio of -2.24 and a beta of 1.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.83. The firm’s 50-day moving average is $3.59 and its two-hundred day moving average is $3.94.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.